Abstract:1162 Objectives Breast cancer is the most frequent cancer and the second-leading cause of cancer death for women in the United States. Human epidermal growth factor receptor 2 (HER2) overexpression is highly associated with the metastasis and malignancy of breast cancer. To detect HER2 expression of tumors in vivo, we developed an agent specifically binds to HER2, 99mTc-labeled H10F, and investigated its capacity for detection of HER2 expression during Herceptin therapy in breast tumors with quantification of SPECT/CT imaging. Methods The HER2-targeted peptide H10F was synthesized by solid phase peptide synthesis and conjugated with a bifunctional chelator HYNIC. The HER2 binding specificity of H10F was verified by immunofluorescence staining of HER2-positive SK-BR3 and HER2-negative MDA-MB-231 cells. HYNIC-H10F was labeled with 99mTc. Then biodistribution and tumor imaging were performed in mice bearing SK-BR3 and MDA-MB-231 human breast cancers, respectively. Results H10F and HYNIC-H10F were characterized by HPLC analysis and mass spectrometry to confirm the structure and purity. Immunofluorescence staining demonstrated FITC-H10F can effectively distinguish different expression of HER2 in SK-BR3 and MDA-MB-231 cells. 99mTc-labeled H10F was prepared with high radiochemical purity (>95%). SPECT/CT imaging showed that the SK-BR3 tumors were clearly visualized (2.46 ± 0.28 %ID/g at 30 min p.i.) while the signals in HER2-negetive MDA-MB-231 tumors were much lower (1.64 ± 0.30 %ID/g at 30 min p.i.). Tumor uptake was higher than all organs except the kidneys at 30 min p.i. Biodistribution studies showed more significant difference in T/NT ratios (4.40 ± 0.29 vs. 2.02 ± 0.47, p Conclusions FITC-H10F specifically binds to HER2 positive tumor cells and 99mTc-HYNIC-H10F accumulates in corresponding tumor model, leading to a distinguished tumor imaging effect of HER2 expression. It suggests that 99mTc-labeled-H10F could be an effective probe for detection of HER2 expression and evaluation of Herceptin involved therapies.

Biodistribution of 131 I-Herceptin in Breast Cancer Xenograft

Experimental Study of the Therapeutic Effectiveness and Mechanism of Bispecific HER2 × CD3 Antibodies to HER2-overexpressing Xenografts in Nude Mice

Biodistribution of ~(131)I-D_2C_5 in nude mice bearing tumor

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

Characteristics in Biodistribution and Metabolism of 131 I Labeled Immunotoxin Against Human Bladder Carcinoma in Tumor-Bearing Nude Mice

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Biodistribution and γ Imaging of ~(125)I-labeled Goat Anti-human IgG Polyclonal Antibody in Nude Mice Bearing Human Colon Cancer Xenografts

Inhibitory Effect of 125I Seed Interstitial Brachytherapy on Human Hepatocarcinoma Cell HepG2 Transplanted Tumor in Nude Mice

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Small-Animal Spect/Ct Imaging with 99Mtc-Hynic-h10f Detects Her2 Expression in Mice Bearing Human Breast Cancers

EXPERIMENTAL STUDY OF INTRATUMOR INJECTION WITH GELATIN MICROSPHERES CONTAINING 131 I AND MITOMYCIN C IN IMPLANTED HEPATOMA-22 IN MICE

The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Study of Distribution and Antisense Imaging for 99Mtc-Ason-egf in Breast Cancer-Bearing Nude Mouse Models

Therapeutic Effect of Herceptin Combined with Cddp on Mice Receiving Implantation of HER-2/neu-overexpression Human Ovarian Cancer

Radioimmunoimaging of human hepatocellular carcinoma xenografts with 131I-anti-HBx monoclonal antibody

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody

[Experimental Study of Radioimmunotherapy for Xenograft of Human Esophageal Carcinoma].

~(125)I/~(111)in Labeled Anti-EGFR Monoclonal Antibody Panitumumab:Preparation and Biodistribution Evaluation in Normal Mice

131I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer